Vaccine Adjuvants Market Size & Share 2025 – 2034

Vaccine Adjuvants Market Size

The global vaccine adjuvants market size was valued at around USD 1.3 billion in 2024 and is estimated to grow at 6.5% CAGR from 2025 to 2034. Vaccine adjuvants such as oils and aluminum salts are integrated into vaccines to optimize the immune response. These adjuvants cause greater immune system stimulation, thus improving vaccine effectiveness. Adjuvants can also make vaccines more efficient and cost-effective by decreasing the amount of antigen needed.

The growing prevalence of certain types of cancer, such as cervical cancer, coupled with the infectious disease pandemic caused by HPV, HIV, tuberculosis, and other serious infections, is expected to tremendously propel the requirement for vaccine adjuvants. For instance, as stated by the American Cancer Society, cervical cancer is the 4th most common cancer in women globally, with 13,820 new cases and 4,360 associated deaths in the year 2024. Such an escalated incidence rate tells of an unwarranted need for effective vaccines and adjuvants for such diseases.
 

Further, with the growing focus on attaining long-lasting immunity towards already existing and potential new diseases, the need and adoption rates for adjuvants are projected to increase as well. The Centers for Disease Control and Prevention (CDC) states that selected vaccines have adjuvants incorporated into their formula to increase the immune response, allowing for a decrease in the necessary amount of antigen or doses. This practicality could facilitate a greater uptake of adjuvanted vaccines.

Vaccine Adjuvants Market Trends

• The research into the preparation of vaccines is placed most actively, and the most attention is paid to the adjuvant purposes due to the low immunogenic reactiveness of the new vaccine antigens.
   
• Such and many other reasons caused the NIH (National Institutes of Health) to reiterate the need to focus on adjuvant research to improve the productivity of vaccines on diseases, especially for elderly and immunocompromised persons. This interest in research is likely to lead to innovation in the design of adjuvants.
   
• In addition, the increasing use of recombinant and artificial vaccines will also contribute to the expansion of the adjuvant market in the foreseeable future.
   
• In the Global Vaccine Action Plan, WHO specifies the improvement, including the creation of new vaccines, and the use of recombinant vaccines. As these highly efficient vaccines are deployed, there is a high chance that demand for adjuvants used in vaccine formulations will increase even more.
   

Vaccine Adjuvants Market Analysis

Based on product type, the market is divided into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other product types. The particulate adjuvants segment dominated the market accounting for 35.4% of revenue share in 2024.
 

• The demand for effective vaccines is on the rise due to the increasing rates of infectious diseases. Over 17 million deaths occur every year around the world due to infectious diseases, as stated by WHO.
   
• Adjuvants in vaccines are known to intensify immune responses, which greatly increases the efficacy of the vaccine. This strengthens the case for particulate adjuvants to solve global health issues.
   
• Moreover, the advancement in materials science as well as technology geared towards improving drug delivery has led to the creation of new types of particulate adjuvants. There is a growing interest in the use of these adjuvants in vaccination development as they can encapsulate antigens and improve their transportation to immune cells.

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the vaccine adjuvants market is segmented into intramuscular, subcutaneous, oral, and other routes of administration. The intramuscular segment accounted for a 59.3% market share in 2024 and is projected for significant growth to reach USD 1.4 billion by 2034.
 

• It is important and essential that vaccines arouse powerful and long-lasting immune responses, especially for those vulnerable to infectious diseases.
   
• Intramuscularly injected adjuvants are proven to elevate immune responses in vaccines and boost their effectiveness. This is especially important when trying to protect various weak populations from harmful infectious diseases.
   
• In addition, global efforts directed towards improving vaccination rates, particularly in the aftermath of the COVID-19 pandemic, have driven the demand for effective vaccine formulations.
• According to the Centers for Disease Control and Prevention (CDC), vaccination against COVID-19 was estimated to have averted around 19.8 million deaths worldwide during the initial year of the vaccine being available.
   
• The combination of intramuscular administration with adjuvants improved the efficacy of the vaccine, which made it a preferred approach in numerous public health programs. This technique has played a significant role in achieving greater immunization coverage, with enhanced protection against infectious diseases globally.
   

Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market with the largest revenue of USD 909.3 million in 2024.
 

• Increasing prevalence of infectious diseases such as viral, bacterial, and parasitic infections has resulted in higher demand for efficient vaccines. There has been increased interest in the use of adjuvants due to the demand for improved strategies for vaccination against COVID-19, influenza, tuberculosis (TB), and other new pathogens.
   
• The WHO noted that approximately 10.8 million people were estimated to be diagnosed with TB in the year 2023, consisting of 6 million men, 3.6 million women, and 1.3 million children. This reinforces the importance of effective vaccines to public health.
   
• Moreover, vaccine efficacy is being enhanced by new technologies in adjuvant formulation such as the invention of new adjuvants such as liposomes, nanoparticles, and other particulate systems.
   
• Adjuvant research was one of the objectives of the Global Vaccine Action Plan 2011-2020 - written by WHO. They make tailored immune responses, which is why they are especially important for infectious disease vaccines.

The U.S. vaccine adjuvants market is projected to grow significantly, reaching USD 927.5 million by 2034.
 

• Vaccine R&D and public health activities in the US are supported by NIH and CDC. These actions purposefully tackle the creation and improvement of adjuvants for infectious disease vaccines.
   
• Additionally, the innovation of vaccine adjuvants is growing due to the collaboration of pharmaceutical companies with research institutions and universities. Such associations are critical in new adjuvant technologies as well as in the optimization of existing formulations.
   
• For instance, TollereBio announced a partnership with the University of Maryland, Baltimore (UMB) in February 2024 for the global licensing of a unique vaccine adjuvant technology. The UMB spin-out sought to commercialize patented technology for accessible and cost-effective vaccine adjuvants using bacterial enzymatic Combinatorial Chemistry (BECC) for both therapeutic and prophylactic vaccines.
   

The vaccine adjuvants market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The pandemic of COVID-19 highlighted how vital vaccines are to public health. For instance, by November 2023, NHS England has reported 11,404,669 COVID vaccinations and 16,190,661 flu vaccinations to have been administered. This has resulted in a shift towards the creation of vaccines against novel and prevalent infectious diseases, implementing adjuvants that are able to activate the immune response geared towards the vaccine.
   
• The goal of the UK is to immunize the most vulnerable through wide-ranging education programs. According to NHS reports, in 2021-2022, 89.2% of children in England underwent the first dose of MMR vaccinations, which demonstrates the results of the established vaccination program.
   
• Moreover, to improve public health, achieving higher vaccination rates requires continuous enhancement of these programs through the incorporation of effective vaccine adjuvants. Adjuvants will make the UK's decisive stance on vaccine research and development cascading, vertically placing UK at the top in immunization strategies development.
   

Japan vaccine adjuvants market is anticipated to witness lucrative growth between 2025 to 2034.
 

• In 2023, the average life expectancy in Japan for women was 87.30 years and 81.09 years for men, making it one of the highest in the world according to WHO. This has contributed to a very old population, with 29.1% of Japanese citizens being 65 years or older in 2023, according to a report from BBC.
   
• The increase in the number of aged individuals influences the need for immunization for disease-targeted vaccines for ever-increasing elderly individuals possessing low immunity. Adjuvants are crucial for accomplishing the needed responses, their most targets are older adults to immunize stronger against infectious diseases.
   

The vaccine adjuvants market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is witnessing a rising incidence of infectious diseases, such as those caused by hepatitis viruses, influenza viruses, and other vaccine-preventable disease pathogens.
   
• According to the National Institutes of Health, in the period from 2006 to 2021, 61,425 acute hepatitis B cases were reported among Saudi nationals, with average annual figures of 3,839. The growing disease burden will compel the development of effective vaccines, subsequently pushing the demand for adjuvants that are used to enhance vaccine efficacy and immune safety. Improved immunotherapy will most certainly generate a sustainable demand for adjuvants in Saudi Arabia.
   
• Furthermore, the Saudi healthcare system is putting an emphasis on vaccination and other preventive healthcare measures. This trend is driving an increase in the rates of adjuvanted vaccines with the hope of immunizing more and more people with better health. In this way, the supply of vaccine adjuvants in Saudi Arabia is expected to rise along with the growth of implementation of these preventive healthcare activities.
   

Vaccine Adjuvants Market Share

The market is broad and includes both large international firms and many smaller companies, making it a prevalent market. A primary focus for market players is directing funds towards the future development of novel vaccine adjuvant technologies, for instance, nanoparticle and toll-like receptor (TLR) agonist and virus-like particle (VLP) adjuvants. These partnerships are crucial with respect to novel technological adoptions and their wider utilization as healthcare providers to moderate the increasing need for affordable and minimally invasive diagnostic techniques. Adequate approval mechanisms provide further incentive to innovate and enter new markets, enabling firms to broaden their scope within the rapidly expanding scope of vaccine adjuvants.
 

Vaccine Adjuvants Market Companies

Some of the eminent market participants operating in the vaccine adjuvants industry include:

• Agenus
• Allergy Therapeutics
• Aurorium
• Brenntag Biosector
• Croda International
• CSL Limited
• Dynavax Technologies Corporation
• EuBiologics
• GSK plc
• Merck KGaA
• Novavax
• OZ Biosciences
• Riboxx GmbH
• Seppic
• SPI Pharma
   

USPs for Tops Players:

• GlaxoSmithKline develops novel adjuvant systems that improve vaccine efficacy as well as the quality and quantity of immune responses.
   
• Novavax is focused on the creation of new adjuvant systems to improve the next generation vaccines' effectiveness.
   
• Seppic is a supplier of safe and effective adjuvants for various types of vaccines.
   

The vaccine adjuvants market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Adjuvant emulsions
• Pathogen components
• Saponin-based adjuvants
• Particulate adjuvants
• Other product types

Market, By Route of Administration

• Intramuscular
• Subcutaneous
• Oral
• Other routes of administration

Market, By Disease Type

• Infectious diseases
• Cancer
• Other diseases

Market, By Application

• Human vaccines
• Veterinary vaccines

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE